The efficacy of angiogenesis inhibitors in breast cancer is limited due to tumor resistance by activation of pre-angiogenic factors (Ruan et al., 2022) and bevacizumab, a humanized anti-VEGF monoclonal antibody, previously approved through FDA’s Accelerated Approval Program for the treatment of metastatic breast cancer had this indication revoked in 2011 due to safety and efficacy concerns (Sasich and Sukkari, 2012). This evidence concerns the gene VEGFA and neoplasm.